Skip to main content
QURE
NASDAQ Life Sciences

uniQure's Huntington's Gene Therapy Shows 80% Slowing of Disease Progression at 36 Months

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$11.75
Mkt Cap
$2.713B
52W Low
$8.73
52W High
$71.5
52W Position info
35% above low
Off High info
84% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

QURE sits 35% above its 52-week low of $8.73.

Summary

uniQure reported new data from its Phase I/II studies of ifezuntirgene inilparvovec (AMT-130) in Huntington's disease. The updated 36-month analysis, now including 15 high-dose patients, showed 80% slowing of disease progression on cUHDRS (nominal p=0.005) and 67% on TFC (p=0.011). At 48 months, the effect was 44% on cUHDRS (p=0.144) and 61% on TFC (p=0.008), with a post-hoc analysis using prior controls showing 53.5% and 68.3% slowing respectively. These results strengthen the BLA submitted earlier this month, though the 48-month cUHDRS miss on significance may raise questions. The company will host a conference call at 8:30 a.m. ET today to discuss the data.

Updates

  1. · SEC 8-K — The 8-K attaches the presentation and press release with the updated 36-month and 48-month AMT-130 data.

At the time of this announcement, QURE was trading at $11.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $8.73 to $71.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

QURE - Latest Insights

QURE
Nov 04, 2026, 7:28 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $22.60
Real-time Price: $23.81 info
Change: +$1.21 (+5%) info
Market Cap: $1.67B info
QURE
Nov 04, 2026, 7:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $22.44
Real-time Price: $23.81 info
Change: +$1.37 (+6%) info
Market Cap: $1.67B info
QURE
Nov 02, 2026, 7:05 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $27.66
Real-time Price: $23.81 info
Change: -$3.85 (-14%) info
Market Cap: $1.67B info
QURE
Sep 29, 2026, 9:26 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $22.00
Real-time Price: $23.81 info
Change: +$1.81 (+8%) info
Market Cap: $1.67B info
QURE
Sep 29, 2026, 9:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $22.20
Real-time Price: $23.81 info
Change: +$1.61 (+7%) info
Market Cap: $1.67B info